


- **SUSPENDED** ALLIANCE A011104** Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (**Feig**)
- **SUSPENDED** UCI 11-21** Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a database (**Su**)
- UCI 15-83** Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (**Tromberg**)
- UCI 11-15** Correlation of Clinical and MRI Findings with Prognosis of Breast Cancer Patients (**Su**)
- UCI 14-86** Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (**Su**)
- UCI 16-23** Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] (**Anton-Culver**)

↑
SCREENING / DIAGNOSTIC / EPIDEMIOLOGIC / INTERVENTIONAL

BREAST CANCER

CORRELATIVE / OBSERVATIONAL
↓

- UCI 95-29** Measurement of Breast Tissue Optical Properties (**Tromberg**)
- UCI 10-24** ATHENA Breast Health Network (**Anton-Culver**)
- UCI 13-19** Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by Mastectomy in Stage I, II, III BREAST CANCER (**Daroui**)
- UCI 16-01** Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (**Nelson**)
- UCI 15-64** A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-Conserving Surgery (**Lin**)
- UCI 17-43** Blood Collection Protocol for Circulating Tumor Cells, Circulating Cancer Associated Fibroblasts and Tissue Factor in Breast Cancer Patients (**Parajuli**)



BREAST CANCER

Multiple Disease Site

UCI 17-90 A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy (**Zhu**)

UCI 17-50 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (**Ou**)

UCI 16-74 A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (**Bota**)

****UCI 18-19** An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies (**Ou**)

Locally Advance / Metastatic

SWOG S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (**Bota**)

ECOG EAY131 Molecular Analysis for Therapy Choice (MATCH) (**Bota**)

NRG BR002 A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (**Daroui**)

UCI 17-79 Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (**Parajuli**)

UCI 18-06 A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment (**Parajuli**)